Clinical Trial

VIsual Pathways Model in Neuro-inflammatory Disorders

Study acronym: VIP-MODEL
Recruiting
View on ClinicalTrials.gov →
Summary
In neuroinflammatory diseases of the central nervous system (CNS) such as multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD) and anti-MOG antibody-associated disorders (MOGAD), neuronal degeneration is the consequence of inflammatory and demyelinating lesions in the brain, optic nerve and spinal cord. Both white and grey matter are systematically affected. Lesions of the perivascular spaces containing cerebrospinal fluid (CSF) and meningeal inflammation seem to play an important role in the pathophysiology of these neuroinflammatory diseases. Currently, the interrelation of all these aspects is not clearly established in the pathophysiology of these diseases. In order to better understand the mechanisms that lead to and underlie the clinical disability of patients with these diseases, we need in vivo study models that allow the in-depth study of the neurodegenerative process and the identification of its causes. In this perspective, we make the hypothesis that the visual pathways model is very relevant to measure neuro-axonal loss and to explore the different mechanisms involved in neurodegeneration during MS and other CNS demyelinating diseases. Researchers have at their disposal many tools that allow them to analyse and quantify the neurodegenerative process in a reproducible and very precise manner from a structural and functional point of view, while taking into account possible vascular involvement (MRI, optical coherence tomography - angiography, etc…).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-08-02; most recent amendment 2025-08-19.
Status change: Not Yet Recruiting → Recruiting 2022-12-12
Trial Details
NCT Number NCT05487989
Lead Sponsor University Hospital, Lille
Conditions Optic Neuritis
Enrollment 100 participants
Start Date 2022-10-07
Primary Completion 2027-04-07 (estimated)
Study Completion 2028-04-07 (estimated)
Updated on ClinicalTrials.gov 2025-08-20